Endocrinology, Vol 130, 159-166, Copyright © 1992 by Endocrine Society

ARTICLES

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

HC Fehmann and JF Habener
Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston 02114.

Glucagon-like peptide-I(7-37) [GLP-I(7-37)] is an intestinal peptide hormone that is released in response to oral nutrients and that potently augments glucose-mediated insulin secretion. GLP-I(7-37) has potent insulin-releasing activities in vivo in response to oral nutrients, in situ in the isolated perfused pancreas, and in vitro in cultured pancreatic B-cells. As such GLP-I(7-37) is a potent hormonal mediator in the enteroinsular axis involved in the regulation of glucose homeostasis. We now show that in addition to stimulating the release of insulin, GLP-I(7-37) stimulates proinsulin gene expression at the levels of gene transcription and cellular levels of proinsulin messenger RNA as well as the translational biosynthesis of proinsulin. These findings of the positive anabolic actions of GLP-I(7-37) on the synthesis of insulin in B-cells support the notion that GLP-I(7-37) may be of therapeutic use in stimulating the production of insulin in patients with noninsulin-dependent diabetes mellitus and that overproduction of insulin with subsequent hypoglycemia will not occur in response to the administration of GLP-I(7-37). Furthermore, these positive actions of GLP-I(7-37) on insulin production obviate the possibility of B-cell exhaustion in response to such a potent secretagogue.

This article has been cited by other articles:

				R. W. Gelling, P. M. Vuguin, X. Q. Du, L. Cui, J. Romer, R. A. Pederson, M. Leiser, H. Sorensen, J. J. Holst, C. Fledelius, et al. Pancreatic {beta}-cell overexpression of the glucagon receptor gene results in enhanced {beta}-cell function and mass Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E695 - E707. [Abstract] [Full Text] [PDF]

				J. Buteau, M. L. Spatz, and D. Accili Transcription Factor FoxO1 Mediates Glucagon-Like Peptide-1 Effects on Pancreatic {beta}-Cell Mass. Diabetes, May 1, 2006; 55(5): 1190 - 1196. [Abstract] [Full Text] [PDF]

				B. N Friedrichsen, N. Neubauer, Y. C Lee, V. K Gram, N. Blume, J. S Petersen, J. H Nielsen, and A. Moldrup Stimulation of pancreatic {beta}-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J. Endocrinol., March 1, 2006; 188(3): 481 - 492. [Abstract] [Full Text] [PDF]

				F. Fehse, M. Trautmann, J. J. Holst, A. E. Halseth, N. Nanayakkara, L. L. Nielsen, M. S. Fineman, D. D. Kim, and M. A. Nauck Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 5991 - 5997. [Abstract] [Full Text] [PDF]

				E. M Sinclair and D. J. Drucker Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential Physiology, October 1, 2005; 20(5): 357 - 365. [Abstract] [Full Text] [PDF]

				C. W Hay, E. M Sinclair, G. Bermano, E. Durward, M. Tadayyon, and K. Docherty Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site J. Endocrinol., August 1, 2005; 186(2): 353 - 365. [Abstract] [Full Text] [PDF]

				K. Dungan and J. B. Buse Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide Clin. Diabetes, April 1, 2005; 23(2): 56 - 62. [Abstract] [Full Text] [PDF]

				C. F. Deacon Therapeutic Strategies Based on Glucagon-Like Peptide 1 Diabetes, September 1, 2004; 53(9): 2181 - 2189. [Abstract] [Full Text] [PDF]

				M. Zander, A. Christiansen, S. Madsbad, and J. Juul Holst Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes Diabetes Care, August 1, 2004; 27(8): 1910 - 1914. [Abstract] [Full Text] [PDF]

				J. J. Holst and J. Gromada Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am J Physiol Endocrinol Metab, August 1, 2004; 287(2): E199 - E206. [Abstract] [Full Text] [PDF]

				M. G. Beconi, A. Mao, D. Q. Liu, C. Kochansky, T. Pereira, C. Raab, P. Pearson, and S.-H. Lee Chiu METABOLISM AND PHARMACOKINETICS OF A DIPEPTIDYL PEPTIDASE IV INHIBITOR IN RATS, DOGS, AND MONKEYS WITH SELECTIVE CARBAMOYL GLUCURONIDATION OF THE PRIMARY AMINE IN DOGS Drug Metab. Dispos., October 1, 2003; 31(10): 1269 - 1277. [Abstract] [Full Text] [PDF]

				E. Oetjen, D. Baun, S. Beimesche, D. Krause, I. Cierny, R. Blume, C. Dickel, S. Wehner, and W. Knepel Inhibition of Human Insulin Gene Transcription by the Immunosuppressive Drugs Cyclosporin A and Tacrolimus in Primary, Mature Islets of Transgenic Mice Mol. Pharmacol., June 1, 2003; 63(6): 1289 - 1295. [Abstract] [Full Text] [PDF]

				R. Lopez de Maturana, A. Willshaw, A. Kuntzsch, R. Rudolph, and D. Donnelly The Isolated N-terminal Domain of the Glucagon-like Peptide-1 (GLP-1) Receptor Binds Exendin Peptides with Much Higher Affinity than GLP-1 J. Biol. Chem., March 14, 2003; 278(12): 10195 - 10200. [Abstract] [Full Text] [PDF]

				K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]

				J. Buteau, S. Foisy, E. Joly, and M. Prentki Glucagon-Like Peptide 1 Induces Pancreatic {beta}-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor Diabetes, January 1, 2003; 52(1): 124 - 132. [Abstract] [Full Text] [PDF]

				A. A. Hardikar, X. Y. Wang, L. J. Williams, J. Kwok, R. Wong, M. Yao, and B. E. Tuch Functional Maturation of Fetal Porcine {beta}-Cells by Glucagon-Like Peptide 1 and Cholecystokinin Endocrinology, September 1, 2002; 143(9): 3505 - 3514. [Abstract] [Full Text] [PDF]

				O. G. Chepurny, M. A. Hussain, and G. G. Holz Exendin-4 as a Stimulator of Rat Insulin I Gene Promoter Activity via bZIP/CRE Interactions Sensitive to Serine/Threonine Protein Kinase Inhibitor Ro 31-8220 Endocrinology, June 1, 2002; 143(6): 2303 - 2313. [Abstract] [Full Text] [PDF]

				M. Tsutsumi, T. H. Claus, Y. Liang, Y. Li, L. Yang, J. Zhu, F. Dela Cruz, X. Peng, H. Chen, S. L. Yung, et al. A Potent and Highly Selective VPAC2 Agonist Enhances Glucose-Induced Insulin Release and Glucose Disposal: A Potential Therapy for Type 2 Diabetes Diabetes, May 1, 2002; 51(5): 1453 - 1460. [Abstract] [Full Text] [PDF]

				J.A. Pospisilik, S.G. Stafford, H-U. Demuth, R. Brownsey, W. Parkhouse, D.T. Finegood, C.H.S. McIntosh, and R.A. Pederson Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and {beta}-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats Diabetes, April 1, 2002; 51(4): 943 - 950. [Abstract] [Full Text] [PDF]

				J. Buteau, S. Foisy, C. J. Rhodes, L. Carpenter, T. J. Biden, and M. Prentki Protein Kinase C{zeta} Activation Mediates Glucagon-Like Peptide-1-Induced Pancreatic {beta}-Cell Proliferation Diabetes, October 1, 2001; 50(10): 2237 - 2243. [Abstract] [Full Text]

				M. Zander, M. Taskiran, M.-B. Toft-Nielsen, S. Madsbad, and J. J. Holst Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 720 - 725. [Abstract] [Full Text]

				W. Moritz, C. A. Leech, J. Ferrer, and J. F. Habener Regulated Expression of Adenosine Triphosphate-Sensitive Potassium Channel Subunits in Pancreatic {beta}-Cells Endocrinology, January 1, 2001; 142(1): 129 - 138. [Abstract] [Full Text] [PDF]

				L. Baggio, T. J. Kieffer, and D. J. Drucker Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in Mice Endocrinology, October 1, 2000; 141(10): 3703 - 3709. [Abstract] [Full Text] [PDF]

				S. SUSINI, G. VAN HAASTEREN, S. LI, M. PRENTKI, and W. SCHLEGEL Essentiality of intron control in the induction of c-fos by glucose and glucoincretin peptides in INS-1 {beta}-cells FASEB J, January 1, 2000; 14(1): 128 - 136. [Abstract] [Full Text]

				T. J. Kieffer and J. F. Habener The adipoinsular axis: effects of leptin on pancreatic beta -cells Am J Physiol Endocrinol Metab, January 1, 2000; 278(1): E1 - E14. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				E. Naslund, J. Bogefors, S. Skogar, P. Gryback, H. Jacobsson, J. J. Holst, and P. M. Hellstrom GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1999; 277(3): R910 - R916. [Abstract] [Full Text] [PDF]

				A. M. F. Salapatek, P. E. MacDonald, H. Y. Gaisano, and M. B. Wheeler Mutations to the Third Cytoplasmic Domain of the Glucagon-Like Peptide 1 (GLP-1) Receptor Can Functionally Uncouple GLP-1-Stimulated Insulin Secretion in HIT-T15 Cells Mol. Endocrinol., August 1, 1999; 13(8): 1305 - 1317. [Abstract] [Full Text]

				C. Montrose-Rafizadeh, P. Avdonin, M. J. Garant, B. D. Rodgers, S. Kole, H. Yang, M. A. Levine, W. Schwindinger, and M. Bernier Pancreatic Glucagon-Like Peptide-1 Receptor Couples to Multiple G Proteins and Activates Mitogen-Activated Protein Kinase Pathways in Chinese Hamster Ovary Cells Endocrinology, March 1, 1999; 140(3): 1132 - 1140. [Abstract] [Full Text]

				J. Seufert, T. J. Kieffer, C. A. Leech, G. G. Holz, W. Moritz, C. Ricordi, and J. F. Habener Leptin Suppression of Insulin Secretion and Gene Expression in Human Pancreatic Islets: Implications for the Development of Adipogenic Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 670 - 676. [Abstract] [Full Text]

				S. Susini, E. Roche, M. Prentki, and W. Schlegel Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic ß(INS-1) cells FASEB J, September 1, 1998; 12(12): 1173 - 1182. [Abstract] [Full Text]

				L. A. Scrocchi and D. J. Drucker Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor-/- Mice Endocrinology, July 1, 1998; 139(7): 3127 - 3132. [Abstract] [Full Text] [PDF]

				P. Briata, R. Van De Werken, I. Airoldi, C. Ilengo, E. Di Blas, E. Boncinelli, and G. Corte Transcriptional Repression by the Human Homeobox Protein EVX1 in Transfected Mammalian Cells J. Biol. Chem., November 17, 1995; 270(46): 27695 - 27701. [Abstract] [Full Text] [PDF]

				G. G. Holz, IV, C. A. Leech, and J. F. Habener Activation of a cAMP-regulated Ca[IMAGE]-Signaling Pathway in Pancreatic [IMAGE]-Cells by the Insulinotropic Hormone Glucagon-like Peptide-1 J. Biol. Chem., July 28, 1995; 270(30): 17749 - 17757. [Abstract] [Full Text] [PDF]

				M. S. Patel and M. Srinivasan Metabolic Programming: Causes and Consequences J. Biol. Chem., January 11, 2002; 277(3): 1629 - 1632. [Full Text] [PDF]